Literature DB >> 6183051

Localization and release of 5-hydroxytryptamine thyrotrophin releasing hormone and substance P in rat ventral spinal cord.

C A Marsden, G W Bennett, J Irons, R F Gilbert, P C Emson.   

Abstract

1. The highest spinal cord levels of 5-hydroxytryptamine (5-HT) and thyrotrophin releasing hormone (TRH) were found in the ventral lumbar cord, in contrast to substance P which was found predominantly in the dorsal cord. 2. 5,6- and 5,7-dihydroxytryptamine, administered into the lateral ventricles reduced 5-HT in the dorsal and ventral spinal cord by up to 90%. 3. There was a parallel reduction in substance P and TRH in ventral spinal cord while methionine-enkephalin and somatostatin in ventral and dorsal cord increased. 4. Reserpine and tetrabenazine depleted 5-HT and partially depleted substance P and TRH in the ventral cord, but had no effect on either methionine-enkephalin or somatostatin. 5. The rates of loss and recovery, after reserpine and tetrabenazine, of 5-HT were different from those of the two peptides. 6. Endogenous 5-HT and TRH release from slices of lumbar cord was enhanced by high potassium. 7. p-Chloroamphetamine and fenfluramine increased 5-HT release but reduced or had no effect on TRH release. The effect of p-chloroamphetamine on TRH release was not dependent on either the presence of 5-HT or 5-HT receptor activity. 8. The results are discussed in terms of the possible co-existence, co-storage and release of 5-HT, substance P and TRH in descending bulbospinal neurones.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183051     DOI: 10.1016/0306-4492(82)90093-4

Source DB:  PubMed          Journal:  Comp Biochem Physiol C        ISSN: 0306-4492


  2 in total

1.  Changes in the behavioural response to a TRH analogue following chronic amitriptyline treatment and repeated electroconvulsive shock in the rat.

Authors:  G W Bennett; A R Green; C Lighton; C A Marsden
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

2.  Motoneurone excitability after administration of a thyrotrophin releasing hormone analogue.

Authors:  K A Clarke; G Stirk
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.